Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome
- PMID: 24574706
- PMCID: PMC3923012
- DOI: 10.3748/wjg.v20.i2.363
Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome
Abstract
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder characterized by unspecific symptoms. In clinical practice it is crucial to distinguish between non-inflammatory functional problems and inflammatory, malignant or infectious diseases of the GI tract. Differentiation between these involves the use of clinical, radiological, endoscopic, histological and serological techniques, which are invasive, expensive, time-consuming and/or hindered by inaccuracies arising from subjective components. A range of faecal markers now appears to have the potential to greatly assist in the differentiation of inflammatory bowel disease (IBD) and IBS. Faecal markers of neutrophil influx into the mucosa are reliable indicators of intestinal inflammation and their role has been mainly studied in discriminating IBD from non-IBD conditions (including IBS) rather than organic from non-organic diseases. Phagocyte-specific proteins of the S100 family (S100A12, calprotectin) are amongst the most promising faecal biomarkers of inflammation. Faecal leukocyte degranulation markers (lactoferrin, polymorphonuclear elastase and myeloperoxidase) have also been suggested as diagnostic tools for the differentiation of IBD and IBS. More recently, additional proteins, including granins, defensins and matrix-metalloproteases, have been discussed as differential diagnostic markers in IBD and IBS. In this review, some of the most promising faecal markers, which have the potential to differentiate IBD and IBS and to advance diagnostic practices, will be discussed.
Keywords: Calprotectin; Defensins; Granins; Irritable bowel syndrome; Lactoferrin; M2-pyruvate kinase; Polymorphonuclear elastase; S100A12.
Figures


Similar articles
-
Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.Gut. 2007 Dec;56(12):1706-13. doi: 10.1136/gut.2006.113431. Epub 2007 Aug 3. Gut. 2007. PMID: 17675327 Free PMC article.
-
Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome.Mymensingh Med J. 2024 Oct;33(4):1149-1156. Mymensingh Med J. 2024. PMID: 39351737
-
Faecal markers of gastrointestinal inflammation.J Clin Pathol. 2012 Nov;65(11):981-5. doi: 10.1136/jclinpath-2012-200901. Epub 2012 Jul 19. J Clin Pathol. 2012. PMID: 22813730 Review.
-
Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?Aliment Pharmacol Ther. 2010 Jun;31(12):1365-70. doi: 10.1111/j.1365-2036.2010.04306.x. Epub 2010 Mar 20. Aliment Pharmacol Ther. 2010. PMID: 20331581
-
Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?Curr Opin Gastroenterol. 2019 Jan;35(1):58-62. doi: 10.1097/MOG.0000000000000493. Curr Opin Gastroenterol. 2019. PMID: 30407259 Review.
Cited by
-
Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12319-32. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26722419 Free PMC article.
-
Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study.Intest Res. 2018 Oct;16(4):554-562. doi: 10.5217/ir.2018.00027. Epub 2018 Oct 10. Intest Res. 2018. PMID: 30301337 Free PMC article.
-
Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.Eur J Clin Microbiol Infect Dis. 2018 Dec;37(12):2341-2346. doi: 10.1007/s10096-018-3381-9. Epub 2018 Sep 21. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30242543 Free PMC article.
-
Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease.J Crohns Colitis. 2022 May 10;16(4):668-681. doi: 10.1093/ecco-jcc/jjab176. J Crohns Colitis. 2022. PMID: 34633041 Free PMC article.
-
Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):78-90. doi: 10.4292/wjgpt.v7.i1.78. World J Gastrointest Pharmacol Ther. 2016. PMID: 26855814 Free PMC article. Review.
References
-
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.e4. - PubMed
-
- Ford AC, Talley NJ. Irritable bowel syndrome. BMJ. 2012;345:e5836. - PubMed
-
- Chang JY, Talley NJ. An update on irritable bowel syndrome: from diagnosis to emerging therapies. Curr Opin Gastroenterol. 2011;27:72–78. - PubMed
-
- Agréus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–680. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous